Halozyme Therapeutics (NASDAQ:HALO) Posts Earnings Results, Beats Expectations By $0.09 EPS

Halozyme Therapeutics (NASDAQ:HALO) released its quarterly earnings data on Thursday. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09, FiscalAI reports. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company had revenue of $492.97 million for the quarter, compared to analyst estimates of $491.63 million. During the same period in the previous year, the company posted $1.72 EPS. The firm’s revenue for the quarter was up 39.1% compared to the same quarter last year.

Here are the key takeaways from Halozyme Therapeutics’ conference call:

• Halozyme reported record third-quarter revenue of $493 million, up 39% year over year, including record royalty revenue of $341 million, up 44%. It raised 2026 revenue, royalty, adjusted EBITDA and non-GAAP EPS guidance, citing continued royalty growth.
• Growth is broadening across the commercial portfolio: established products DARZALEX, VYVGART Hytrulo and PHESGO continued to grow, while newer launches OCREVUS ZUNOVO, OPDIVO Qvantig and RYBREVANT FASPRO added to royalties. Halozyme highlighted further conversion potential for the newer products, though adoption and sales projections are based on partner commentary.
• ENHANZE partners added four target nominations, and Halozyme had 12 programs in clinical development, with a 13th expected by year-end. The company also expects the first two Hypercon partner programs to enter Phase I in the first half of 2027; Aerocon remains earlier-stage, with clinical entry targeted for the second half of 2028.
• A Dutch court found Merck’s KEYTRUDA QLEX infringed Halozyme’s EP622 patent and barred specified Merck entities from infringing in several European markets; Halozyme said the ruling supports its position in Europe. The company noted that U.S. patent proceedings have produced adverse initial rulings and that its expected appeal process could continue until 2028.
• Halozyme ended the quarter with $1.08 billion in cash and marketable securities, $3.3 billion in long-term debt and 2.4x net leverage after completing a $1.5 billion convertible-note offering. It also repurchased $400 million of shares in 2026 and said it remains focused on investing in its platforms and deleveraging.

Halozyme Therapeutics Price Performance

NASDAQ:HALO traded down $15.48 during midday trading on Friday, hitting $107.48. The company had a trading volume of 2,106,688 shares, compared to its average volume of 1,950,360. The company has a market capitalization of $12.20 billion, a PE ratio of 31.99, a P/E/G ratio of 0.49 and a beta of 0.92. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics has a 52-week low of $61.22 and a 52-week high of $134.00. The stock’s fifty day moving average price is $115.26 and its 200-day moving average price is $84.57.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Revenue rose 39% year over year to a record $493 million, while royalty revenue grew 44% to $341 million. Adjusted earnings of $2.39 per share also topped the roughly $2.30 consensus estimate. Halozyme Q3 results and guidance
• Positive Sentiment: Halozyme raised its 2026 guidance, forecasting $1.86 billion–$1.925 billion in revenue and non-GAAP EPS of $8.75–$9.05. It also expanded ENHANZE collaboration agreements with three existing partners, with three programs advancing into Phase 1 development. Halozyme Q3 earnings and guidance
• Negative Sentiment: HALO fell after the earnings release even though results exceeded estimates and guidance increased. The available reports flag the share-price decline but do not identify a specific reason for the negative market reaction. Halozyme sales surprise, but stock drops

Analyst Ratings Changes

A number of brokerages have recently issued reports on HALO. Zacks Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Wells Fargo & Company increased their target price on shares of Halozyme Therapeutics from $95.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Friday. HC Wainwright increased their target price on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. Finally, Stifel Nicolaus set a $130.00 price target on shares of Halozyme Therapeutics in a report on Friday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $106.09.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $109.40, for a total value of $2,188,000.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $83,995,132. This trade represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,852 shares of company stock worth $13,538,046 over the last 90 days. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.